%PDF-1.6
%
1 0 obj
<<
/Lang (de)
/MarkInfo <<
/Marked true
>>
/Metadata 2 0 R
/Outlines 3 0 R
/PageLayout /OneColumn
/PageMode /UseOutlines
/Pages 4 0 R
/StructTreeRoot 5 0 R
/Type /Catalog
/ViewerPreferences <<
/DisplayDocTitle true
>>
>>
endobj
6 0 obj
<<
/Author (Gemeinsamer Bundesausschuss/Federal Joint Committee \(g-ba.de\))
/Category ()
/Comments ()
/Company ()
/CreationDate (D:20230509104134+02'00')
/Creator <4163726F626174205044464D616B65722032302066FC7220576F7264>
/Keywords <416E6E65782058494920852042656E65666974204173736573736D656E74206F66204D65646963696E616C2050726F64756374732077697468204E65772041637469766520496E6772656469656E7473206163636F7264696E6720746F2053656374696F6E203335612053474220560D0A526176756C697A756D616220284E657720746865726170657574696320696E6469636174696F6E3A206D7961737468656E6961206772617669732C20616E74692D4143685220616E7469626F64792D706F73697469766529>
/Manager ()
/ModDate (D:20230517100949+02'00')
/Producer (Adobe PDF Library 20.5.3)
/SourceModified (D:20230505082203)
/Subject (Pharmaceuticals Directive:)
/Title (Resolution)
/_DocHome (1460877555)
>>
endobj
2 0 obj
<<
/Length 5059
/Subtype /XML
/Type /Metadata
>>
stream
2023-05-17T10:09:49+02:00
2023-05-09T10:41:34+02:00
2023-05-17T10:09:49+02:00
Acrobat PDFMaker 20 für Word
uuid:7d7301ec-5dd3-4688-bcfe-8b22a42e94a8
uuid:fac880f5-eb82-495b-ab4c-cc43f2b373ce
9
application/pdf
Resolution
Pharmaceuticals Directive:
Gemeinsamer Bundesausschuss/Federal Joint Committee (g-ba.de)
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ravulizumab (New therapeutic indication: myasthenia gravis
anti-AChR antibody-positive)
Adobe PDF Library 20.5.3
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ravulizumab (New therapeutic indication: myasthenia gravis, anti-AChR antibody-positive)
D:20230505082203
1460877555
Arzneimittel-Richtlinie: Anlage XII â•fi Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V
endstream
endobj
3 0 obj
<<
/Count 12
/First 7 0 R
/Last 8 0 R
/Type /Outlines
>>
endobj
4 0 obj
<<
/Count 5
/Kids [9 0 R 10 0 R 11 0 R 12 0 R 13 0 R]
/Type /Pages
>>
endobj
5 0 obj
<<
/K 14 0 R
/ParentTree 15 0 R
/ParentTreeNextKey 10
/RoleMap 16 0 R
/Type /StructTreeRoot
>>
endobj
7 0 obj
<<
/A 17 0 R
/Next 18 0 R
/Parent 3 0 R
/Title (Resolution)
>>
endobj
8 0 obj
<<
/A 19 0 R
/Count 2
/First 20 0 R
/Last 21 0 R
/Parent 3 0 R
/Prev 22 0 R
/Title (II. Entry into force)
>>
endobj
9 0 obj
<<
/Contents [23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
>>
/XObject <<
/OL1 36 0 R
/OL2 37 0 R
>>
>>
/Rotate 0
/StructParents 0
/Tabs /S
/Type /Page
>>
endobj
10 0 obj
<<
/Annots [38 0 R]
/Contents [39 0 R 40 0 R 41 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
/TT3 42 0 R
>>
/XObject <<
/OL1 36 0 R
/OL2 37 0 R
>>
>>
/Rotate 0
/StructParents 1
/Tabs /S
/Type /Page
>>
endobj
11 0 obj
<<
/Annots [43 0 R 44 0 R]
/Contents [45 0 R 46 0 R 47 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/C2_0 48 0 R
/C2_1 49 0 R
/TT0 33 0 R
/TT1 34 0 R
/TT2 50 0 R
/TT3 51 0 R
/TT4 52 0 R
/TT5 35 0 R
>>
/XObject <<
/OL1 36 0 R
/OL2 37 0 R
>>
>>
/Rotate 0
/StructParents 2
/Tabs /S
/Type /Page
>>
endobj
12 0 obj
<<
/Contents [53 0 R 54 0 R 55 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
>>
/XObject <<
/OL1 36 0 R
/OL2 37 0 R
>>
>>
/Rotate 0
/StructParents 5
/Tabs /S
/Type /Page
>>
endobj
13 0 obj
<<
/Annots [56 0 R 57 0 R]
/Contents [58 0 R 59 0 R 60 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
/TT3 42 0 R
>>
/XObject <<
/OL1 36 0 R
/OL2 37 0 R
>>
>>
/Rotate 0
/StructParents 6
/Tabs /S
/Type /Page
>>
endobj
14 0 obj
<<
/K [61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R
71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R
81 0 R 82 0 R 83 0 R 84 0 R 85 0 R 86 0 R 87 0 R 88 0 R 89 0 R 90 0 R
91 0 R 92 0 R 93 0 R 94 0 R 95 0 R 96 0 R 97 0 R 98 0 R 99 0 R 100 0 R
101 0 R 102 0 R 103 0 R 104 0 R 105 0 R 106 0 R 107 0 R 108 0 R 109 0 R 110 0 R
111 0 R 112 0 R 113 0 R 114 0 R 115 0 R 116 0 R 117 0 R 118 0 R 119 0 R 120 0 R
121 0 R 122 0 R 123 0 R 124 0 R 125 0 R 126 0 R 127 0 R 128 0 R]
/P 5 0 R
/S /Sect
>>
endobj
15 0 obj
<<
/Nums [0 [61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R]
1 [70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R
80 0 R 81 0 R 82 0 R null null 129 0 R null null 84 0 R 85 0 R
86 0 R 88 0 R 89 0 R 90 0 R 91 0 R 92 0 R null 130 0 R null 131 0 R
null null 132 0 R null 133 0 R null 134 0 R null null 135 0 R
null 136 0 R null 137 0 R null 138 0 R null 139 0 R 140 0 R 141 0 R
null 142 0 R null 143 0 R 144 0 R 145 0 R null 146 0 R null 147 0 R
86 0 R]
2 [null 148 0 R null 149 0 R 150 0 R 151 0 R null 152 0 R null 153 0 R
154 0 R 155 0 R null 156 0 R null 157 0 R null 158 0 R null 159 0 R
null 160 0 R null 161 0 R null 162 0 R null 163 0 R null 164 0 R
94 0 R 95 0 R 96 0 R 97 0 R 98 0 R null 165 0 R 99 0 R 100 0 R 101 0 R
102 0 R 103 0 R 104 0 R 105 0 R]
3 165 0 R 4 165 0 R
5 [106 0 R 107 0 R 108 0 R 109 0 R null 166 0 R null 167 0 R null null
168 0 R null 169 0 R null 170 0 R null 171 0 R null 172 0 R null
173 0 R null 174 0 R null 175 0 R 176 0 R null 177 0 R null 178 0 R
null 179 0 R null 180 0 R null 181 0 R 182 0 R 183 0 R null 184 0 R
null 185 0 R 186 0 R 111 0 R 112 0 R 113 0 R null 187 0 R null 188 0 R
null 189 0 R null null 190 0 R null 191 0 R null null 192 0 R
null 193 0 R null 194 0 R null null 195 0 R null 196 0 R null
197 0 R null null 198 0 R null 199 0 R null 200 0 R null 201 0 R
null null 202 0 R null 203 0 R null 204 0 R null 205 0 R null
206 0 R null 207 0 R null 208 0 R null 209 0 R null 210 0 R null
211 0 R 212 0 R 213 0 R 214 0 R 215 0 R 216 0 R null 217 0 R null 218 0 R
null 219 0 R null 220 0 R null 221 0 R 222 0 R 223 0 R 224 0 R 225 0 R
226 0 R 115 0 R]
6 [116 0 R 117 0 R 118 0 R null null 227 0 R null null 120 0 R 121 0 R
122 0 R 123 0 R 124 0 R 228 0 R 124 0 R 125 0 R 126 0 R 127 0 R 128 0 R]
7 228 0 R 8 228 0 R 9 147 0 R]
>>
endobj
16 0 obj
<<
/Annotation /Span
/Artifact /P
/Bibliography /BibEntry
/Chart /Figure
/Diagram /Figure
/DropCap /Figure
/Endnote /Note
/Footnote /Note
/InlineShape /Figure
/Outline /Span
/Strikeout /Span
/Subscript /Span
/Superscript /Span
/TextBox /Art
/Underline /Span
>>
endobj
17 0 obj
<<
/D [9 0 R /XYZ 69 743 0.0]
/S /GoTo
>>
endobj
18 0 obj
<<
/A 229 0 R
/Next 230 0 R
/Parent 3 0 R
/Prev 7 0 R
/Title (of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:)
>>
endobj
19 0 obj
<<
/D [13 0 R /XYZ 69 463 0.0]
/S /GoTo
>>
endobj
20 0 obj
<<
/A 231 0 R
/Next 21 0 R
/Parent 8 0 R
/Title (1. The resolution will enter into force on the day of its publication on the website of the G-BA on 20 April 2023.)
>>
endobj
21 0 obj
<<
/A 232 0 R
/Parent 8 0 R
/Prev 20 0 R
/Title (2. The period of validity of the resolution is limited to 1 November 2023.)
>>
endobj
22 0 obj
<<
/A 233 0 R
/Count 5
/First 234 0 R
/Last 235 0 R
/Next 8 0 R
/Parent 3 0 R
/Prev 230 0 R
/Title (I. In Annex XII, the following information shall be added after No. 4 to the information on the benefit assessment of Ravulizumab in accordance with the resolution of 18 March 2022:)
>>
endobj
23 0 obj
<<
/Length 37
/Filter /FlateDecode
>>
stream
x+*23P0bdBr.KB W
endstream
endobj
24 0 obj
<<
/Length 57
/Filter /FlateDecode
>>
stream
x+*23P0bLA(fd[*($r)*+rr jx
endstream
endobj
25 0 obj
<<
/Length 784
/Filter /FlateDecode
>>
stream
HUn0+H"%J@ i=6hdc
GNN{lh0b>D!b[t12^kr HEآI,7M̐_tHt}3
N
,2aU!M fs